Quotient Clinical, part of Quotient Bioresearch ("Quotient") announced today that it has received approval of the final patent for its Enterion™ technology. This completes a portfolio of eight granted patents across North America and Europe, with a lifetime extending through to 2020.

The Enterion capsule has been developed to investigate the absorption of drugs from the gastrointestinal (GI) tract.  It is a remote-controlled device that is capable of precisely delivering pharmaceutically relevant drug formulations (both liquids and solids) to specific sites within the GI tract. The information gained from these studies provides formulation scientists and clinical development teams with invaluable insights in order to guide the development of optimized drug products for oral administration.

Since its invention, Enterion has been used in over 120 clinical studies that have involved the dosing of over four thousand Enterion capsules to healthy volunteers at Quotient's clinical facility in Nottingham, UK.  

Mark Egerton, Managing Director, Quotient Clinical says: "Approval of this final patent represents a key milestone in our Enterion program. The technology has been in routine use for several years and reinforces our commitment to deliver innovative solutions for our customers. It is gratifying that Enterion has been deployed in development programs for many of the breakthrough medicines in the industry's pipeline today."

For further information click here